Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Molecular Medicine (Berlin, Germany)|May 25, 2010
Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shockAnje Cauwels, Elke Rogge, Ben Janssen, et al.Plos One|September 10, 2013
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systemsBenjamin Vandendriessche, Elke Rogge, Vera Goossens, et al.Critical Care Medicine|April 11, 2014
A multiscale entropy-based tool for scoring severity of systemic inflammationBenjamin Vandendriessche, Harlinde Peperstraete, Elke Rogge, et al.Cardiovascular Research|June 22, 2013
TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide productionAnje Cauwels, Benjamin Vandendriessche, Jennyfer Bultinck, et al.Cellular and Molecular Life Sciences : CMLS|January 20, 2019
A novel leptin receptor antagonist uncouples leptin's metabolic and immune functionsLennart Zabeau, Joris Wauman, Julie Dam, et al.Journal of Autoimmunity|November 24, 2018
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in miceAnje Cauwels, Sandra Van Lint, Dominiek Catteeuw, et al.Scientific Reports|November 4, 2021
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAEAnje Cauwels, Sandra Van Lint, Elke Rogge, et al.Cardiovascular Research|March 15, 2008
Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout miceEmmanuel S Buys, Patrick Sips, Pieter Vermeersch, et al.Experimental Hematology & Oncology|June 3, 2024
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphomaWillem Daneels, Alexander Van Parys, Leander Huyghe, et al.Oncoimmunology|February 6, 2018
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironmentAnje Cauwels, Sandra Van Lint, Geneviève Garcin, et al.Pageof 2